Innova Captab

Innova Captab Liabilities

The The Liabilities of Innova Captab (INNOVACAP.NS) as of Nov 22, 2026 is 7.47 B INR. In the previous year, The Liabilities was 6.21 B INR — a change of 20.23% (higher).

Liabilities

7.47 BINR

YoY

20.23%

Last updated:

In 2026, Innova Captab's total liabilities amounted to 7.47 B INR, a 20.23% difference from the 6.21 B INR total liabilities in the previous year.

The Innova Captab Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2019
2.98 B INR
Jan 1, 2020
1.71 M INR
Jan 1, 2021
2.25 B INR
Jan 1, 2022
3.67 B INR
Jan 1, 2023
6.93 B INR
Jan 1, 2024
4.90 B INR
Jan 1, 2025
6.21 B INR
Jan 1, 2026
7.47 B INR
The Innova Captab Liabilities history
YEARLiabilitiesYoY
7.47 BINR+20.23%
6.21 BINR+26.74%
4.90 BINR-29.31%
6.93 BINR+88.93%
3.67 BINR+63.20%
2.25 BINR+131,359.06%
1.71 MINR-99.94%
2.98 BINR+113.03%
1.40 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Innova Captab Stock analysis

What does Innova Captab do? Innova Captab Ltd generates revenue through its CDMO business, which offers research, product development, and manufacturing services to clients in the pharmaceutical sector. The company also earns from its domestic branded generics business, developing, manufacturing, and distributing generic formulation products under its own brand names across India via online and offline channels. Additionally, Innova Captab sells its generic drug products through various e-commerce pharmacy sites. The company's diversified portfolio includes tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. Its international branded generic product business focuses on exporting branded generic products globally. Innova Captab's primary customers are pharmaceutical companies seeking CDMO services, Indian consumers purchasing generic medicines through retail and online pharmacies, and international buyers of branded generic products. The domestic market segment is served through branded generics sold under the company's own brand names, while the international segment targets global markets for branded generic drug exports. The company's value chain spans research and development, manufacturing, drug distribution, marketing, and exports, ensuring comprehensive coverage across the pharmaceutical industry. The company's product segments include CDMO services, domestic branded generics, and international branded generics. CDMO services are provided to pharmaceutical firms requiring outsourced research and manufacturing. Domestic branded generics are marketed in India under the company's brand names through both online and offline channels. International branded generics are exported to global markets, leveraging the company's manufacturing capabilities and product portfolio. Innova Captab's business model integrates all stages of the pharmaceutical value chain, from R&D to exports, to deliver a full-service solution for its clients and customers. Innova Captab is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Innova Captab's Liabilities

Innova Captab's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Innova Captab's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Innova Captab's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Innova Captab's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Innova Captab’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Innova Captab stock

The Liabilities of Innova Captab is 7.47 B INR in 2026.

The Liabilities of Innova Captab changed from 6.21 B INR to 7.47 B INR, representing a 20.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Innova Captab since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Innova Captab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Innova Captab

All Key Metrics — Innova Captab